Two groups, totalling 64 patients, were examined in an attempt to correlate the timed dosage of d-tubocurarine with plasma protein measurements. When dosage requirements were assessed on clinical grounds, three significant correlations emerged, but there were none when neuromuscular response was held at zero.
It is suggested that twitch response could be held at a steady level of depression to obtain a time-limited dose of relaxant, enabling dosage comparisons to be made with non-depolarisers.
References
1.
AladjemoffL., DiksteinS., and ShafrirE. (1958): “Binding of tubocurarine to plasma proteins”, J. Pharmacol, exp. Ther., 123, 43.
2.
BarakaA., and GabaliF. (1968): “Correlation between tubocurarine requirements and plasma protein pattern”, Brit. J. Anaesth., 40, 89.
3.
BrunnerE. A., and BadolaR. P. (1969): “A simple muscle-twitch monitor”, Anesthesiol., 31, 466.
4.
CohenE. N., CorbascioA., and FleischliG. (1965): “The distribution and fate of tubocurarine”, J. Pharmacol. exp. Ther., 147, 120.
5.
DundeeJ. W., and GrayT. C. (1953): “Resistance to d-tubocurarine chloride in the presence of liver damage”, Lancet, 2, 16.
6.
El-HakimM., and BarakaA. (1963): “d-Tubo-curarine in liver disease”, Kasr-El-Anini J. Surg., 4, 99.
7.
GoldsteinA. (1949): “The interactions of drugs and plasma proteins”, Pharm. Rev., 1, 102.
8.
KatzR. L. (1965): “Comparison of electrical and mechanical recording of spontaneous and evoked muscle activity”, Anesthesiol., 26, 204.
9.
KraemerR. J., GalvezT., and PhernettonT. (1971): “The abolishment of curare-induced neuromuscular blockade by plasma phoresis accompanied by alterations in curare binding by plasma proteins”, Fed. Proc., 30, 558.
10.
StovnerJ., TheodorsenL., and BjelkeE. (1971): “Sensitivity to tubocurarine and alcuronium with special reference to plasma protein pattern”, Brit. J. Anaesth., 43, 385.
